A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENTIN RECURRENT GLIOBLA STOMA: THE DUTCH BELOB STUDY

被引：0
|
作者：
Taal, Walter [1 ]
Oosterkamp, H. [2 ]
Walenkamp, Annemieke [3 ]
Beerenpoot, Lucas [4 ]
Hanse, Monique [5 ]
Buter, Jan [6 ]
Honkoop, Aafke [7 ]
Boerman, Dolf [8 ]
de Vos, Filip [9 ]
Jansen, R. [10 ]
van der Berkmortel, Franchette [11 ]
Brandsma, Dieta [12 ]
Enting, Roelien [3 ]
Kros, Johan [1 ]
Bromberg, Jacoline [1 ]
van Heuvel, Irene [1 ]
Smits, Marion [1 ]
van der Holt, Ronnie [1 ]
Vernhout, Rene [1 ]
van den Bent, Martin [1 ]
机构：
[1] ErasmusMC, Rotterdam, Netherlands
[2] MCHaaglanden, The Hague, Netherlands
[3] Univ Med Ctr Groningen, Groningen, Netherlands
[4] St Elizabeth Hosp, Tilburg, Netherlands
[5] Catharina Hosp, Eindhoven, Netherlands
[6] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[7] Isala Klin, Zwolle, Netherlands
[8] Rijnstate Hosp, Arnhem, Netherlands
[9] UMCU, Utrecht, Netherlands
[10] MUCM, Maastricht, Netherlands
[11] Atrium Hosp, Heerlen, Netherlands
[12] Dutch Canc Inst, Amsterdam, Netherlands
来源：
NEURO-ONCOLOGY | 2013年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：83 / 84
页数：2
相关论文
共 50 条
  • [41] Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma: A Nationwide Population-Based Study
    Lee, Yeonhu
    Lee, Eunyoung
    Roh, Tae Hoon
    Kim, Se-Hyuk
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (34)
  • [42] BEVACIZUMAB ALONE VERSUS BEVACIZUMAB PLUS IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A NATIONWIDE POPULATION-BASED STUDY
    Lee, Yeonhu
    Roh, Tae Hoon
    Kim, Se-Hyuk
    NEURO-ONCOLOGY, 2023, 25
  • [43] BEVACIZUMAB ALONE VERSUS BEVACIZUMAB PLUS IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A NATIONWIDE POPULATION-BASED STUDY
    Lee, Yeonhu
    Roh, Tae Hoon
    Kim, Se-Hyuk
    NEURO-ONCOLOGY, 2023, 25
  • [44] ENZASTAURIN (ENZ) VERSUS LOMUSTINE (CCNU) IN THE TREATMENT OF RECURRENT, INTRACRANIAL GLIOBLASTOMA (GBM): A PHASE III STUDY
    Wick, W.
    Puduvalli, V. K.
    Chamberlain, M.
    Carpentier, A.
    Cher, L.
    Mason, W.
    Van den Bent, M.
    Hong, S.
    Thornton, D.
    Fine, H.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1068 - 1068
  • [45] RANDOMIZED PHASE 2 EVALUATION OF BEVACIZUMAB VERSUS BEVACIZUMAB/FOSBRETABULIN IN RECURRENT OVARIAN, TUBAL OR PERITONEAL CARCINOMA: A GYNECOLOGIC ONCOLOGY GROUP STUDY
    Monk, B.
    Sill, M.
    Walker, J.
    DiSilvestro, P.
    Sutton, G.
    Tewari, K.
    Pajon, E.
    Martin, L.
    Schilder, J.
    Coleman, R.
    Balkssoon, J.
    Aghajanian, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 42 - 43
  • [46] A RANDOMIZED PHASE II STUDY OF CARBOPLATIN AND BEVACIZUMAB IN RECURRENT GLIOBLASTOMA MULTIFORME ( CABARET STUDY)
    Field, Kathryn M.
    Cher, Lawrence
    Wheeler, Helen
    Hovey, Elizabeth
    Nowak, Anna K.
    Simes, John
    Sawkins, Kate
    France, Trevor
    Brown, Chris
    NEURO-ONCOLOGY, 2011, 13 : 88 - 88
  • [47] Comment on Chun et al, "A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases"
    Gelsomino, Fabio
    Spallanzani, Andrea
    Casadei-Gardini, Andrea
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : E262 - E263
  • [48] Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.
    Gorbunova, Vera
    Beck, Thaddeus
    Hofheinz, Ralf
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET)
    Field, Kathryn Maree
    Simes, John
    Wheeler, Helen
    Hovey, Elizabeth J.
    Nowak, Anna K.
    Cher, Lawrence
    Brown, Chris
    Livingstone, Ann
    Sawkins, Kate
    Rosenthal, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Gorbunova, Vera
    Beck, J. Thaddeus
    Hofheinz, Ralf-Dieter
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    Mangel, Laszlo
    Fernandez, Elena Elez
    Deming, Dustin A.
    Ramanathan, Ramesh K.
    Torres, Alison H.
    Sullivan, Danielle
    Luo, Yan
    Berlin, Jordan D.
    BRITISH JOURNAL OF CANCER, 2019, 120 (02) : 183 - 189
12345